MetaCap

Novo Nordisk A/S (NVO)

NYSE: NVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

37.82-1.05 (-2.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NVO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$166.69B
Dividend yield
30.94% ($11.70)
Ex-dividend date
Aug 17, 2026
52-week range
35.12 – 64.16
Day range
37.75 – 39.11
Volume / Avg
13.04M / 12.59M
Beta
—
Next earnings
Feb 3, 2027

52-week range

$35.12$64.16

NVO stock today

Shares of Novo Nordisk A/S (NVO) finished lower on Nov 20 at $37.82, a drop of 2.70% or $1.05 per share, versus the S&P 500's 3.70% decline. Shares are 41.1% below their 52-week high of $64.16, set on Jan 23, 2026 and 7.7% above the 52-week low of $35.12, near the bottom of the past year's range. NVO is down 25.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.6%.

At 9.6x trailing earnings, Novo Nordisk A/S trades below the peer-group median of 23.1x. Its forward P/E of 10.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Novo Nordisk A/S's next earnings report is expected on Feb 3, 2027. Novo Nordisk A/S pays an annual dividend of $11.70 per share, a 30.94% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Novo Nordisk A/S

Company profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Maziar Mike Doustdar B.A.
Headquarters
Bagsvaerd
Employees
68,794

Analyst forecast

Forecast

Consensus (14 analysts)

hold

Avg. price target

$45.49+20.28%

  • Strong buy 0
  • Buy 3
  • Hold 10
  • Sell 1
  • Strong sell 0

Target range

Low $39.54High $64.26

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Feb 3, 2027
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$1.02 vs $0.81
Surprise
+25.93%

Dividends

Dividend history
Annual dividend
$11.70
Last payment
$0.579
Ex-dividend date
Aug 17, 2026

NVO news

All NVO news

Novo Nordisk A/S peers

Health Care sector
NVO peer companies
CompanyPrice% ChgMarket capCompare
PFEPfizer Inc.27.40-0.51%$156.18Bvs NVO
ABTAbbott Laboratories103.00-0.84%$178.39Bvs NVO
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs NVO
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs NVO
SNYSanofi ADS46.52+1.00%$111.70Bvs NVO
GSKGSK plc ADR47.76-0.13%$95.73Bvs NVO
REGNRegeneron Pharmaceuticals Inc.920.69-0.19%$95.24Bvs NVO
TAKTakeda Pharmaceutical Company Limited ADR21.77+1.68%$69.55Bvs NVO

Indexes, lists and sector

Novo Nordisk A/S stock FAQ

What is Novo Nordisk A/S's stock price today?

NVO last traded at $37.82 as of Nov 20, 4:00 PM EST, down 2.70% on the day. Prices are delayed at least 15 minutes.

Does Novo Nordisk A/S pay a dividend?

Yes. Novo Nordisk A/S pays $11.70 per share annually, a 30.94% yield. The most recent dividend of $0.579 had an ex-dividend date of Aug 17, 2026.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is expected to report earnings on Wednesday, February 3, 2027.

What is NVO's P/E ratio?

NVO trades at a trailing P/E ratio of 9.55 and a forward P/E of 10.77, compared with a median of 23.1 for its closest peers.

Who is Novo Nordisk A/S's CEO?

Mr. Maziar Mike Doustdar B.A. is the chief executive officer of Novo Nordisk A/S, which has about 68,794 employees.

Has NVO ever split its stock?

Yes. The most recent NVO stock split was a 2-for-1 split on Sep 20, 2023, one of 5 splits on record.

What is the NVO 52-week high?

The 52-week high for NVO is $64.16 and the 52-week low is $35.12. The stock is currently 41.1% below its high.

Compare NVO